Back to Clinical Trials
Phase 1Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Sponsored by Bristol-Myers Squibb

About this study

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Where this study is enrolling (8)

  • Community Cancer Institute

    Clovis, California

    Call 559-387-1600

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

    Call 323-865-3967

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

    Call 949-764-8222

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • University of Iowa

    Iowa City, Iowa

    Call 319-356-1032

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • John Theurer Cancer Center

    Hackensack, New Jersey

    Call 551-996-5863

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Show all 8 locations

  • Providence Cancer Center Oncology and Hematology Care- Eastside

    Portland, Oregon

    Call 503-215-5696

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Vanderbilt University Medical Center

    Nashville, Tennessee

    Call 615-936-1796

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Houston Methodist Hospital

    Houston, Texas

    Call 713.790.3311

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Who can participate

Inclusion criteria

  • ✓Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.
  • ✓Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
  • ✓Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • ✓Radiographically documented progressive disease on or after the most recent therapy.
  • ✓Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.
  • ✓Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.

Exclusion criteria

  • ✕Women who are pregnant or breastfeeding.
  • ✕Primary central nervous system (CNS) malignancy.
  • ✕Untreated CNS metastases.
  • ✕Leptomeningeal metastases.
  • ✕Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment.
  • ✕Active, known, or suspected autoimmune disease.
  • ✕Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment.
  • ✕Prior organ or tissue allograft.
  • ✕Uncontrolled or significant cardiovascular disease.
  • ✕Major surgery within 4 weeks of study drug administration.
  • ✕History of or with active interstitial lung disease or pulmonary fibrosis.
  • ✕Other protocol-defined inclusion/exclusion criteria apply.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.